$BRNS
Barinthus Biotherapeutics PLC Stock $brns

$brns Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000182818524000075 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$14.97M	$0.00	$334.0K
YoY Change		-100.0%	-98.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.42M	$7.201M	$13.13M
YoY Change	1296.46%	-45.15%	-303.69%
% of Gross Profit
Research & Development	$11.14M	$11.66M	$13.54M
YoY Change	-26.45%	-13.89%	39.33%
% of Gross Profit
Depreciation & Amortization	$700.0K	$700.0K	$500.0K
YoY Change	0.0%	40.0%	-49.6%
% of Gross Profit
Operating Expenses	$24.56M	$18.86M	$26.67M
YoY Change	52.49%	-29.28%	714.38%
Operating Profit	-$9.380M	-$18.29M	-$26.34M
YoY Change	-41.76%	-30.57%	-299.0%
Interest Expense	$614.0K	$623.0K	$508.0K
YoY Change	224.87%	22.64%	366.06%
% of Operating Profit
Other Income/Expense, Net	$1.248M	$1.336M	$1.377M
YoY Change	-10.34%	-2.98%	57.01%
Pretax Income	-$8.132M	-$16.95M	-$24.96M
YoY Change	-44.73%	-32.09%	-268.95%
Income Tax	-$3.000K	-$7.000K	-$1.136M
% Of Pretax Income
Net Earnings	-$8.114M	-$16.93M	-$23.80M
YoY Change	-42.34%	-28.87%	-251.67%
Net Earnings / Revenue	-54.21%		-7126.35%
Basic Earnings Per Share	-$0.21	-$0.43	-$0.62
Diluted Earnings Per Share	-$0.21	-$0.43	-$0.62
COMMON SHARES
Basic Shares Outstanding	39.41M shares	39.03M shares	38.37M
Diluted Shares Outstanding	39.42M shares	39.04M shares	38.41M

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.1M	$117.8M	$173.0M
YoY Change	-33.81%	-31.93%	-10.03%
Cash & Equivalents	$106.1M	$117.8M	$173.0M
Short-Term Investments
Other Short-Term Assets	$464.0K	$626.0K	$1.446M
YoY Change	30.7%	-56.71%	-86.39%
Inventory
Prepaid Expenses	$7.064M	$7.813M	$6.762M
Receivables	$14.97M		$349.0K
Other Receivables	$6.055M		$3.190M
Total Short-Term Assets	$134.7M	$131.9M	$184.8M
YoY Change	-21.28%	-28.63%	-18.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.72M	$10.96M	$13.74M
YoY Change	-12.63%	-20.22%	-10.67%
Goodwill	$12.21M	$12.21M	$12.21M
YoY Change	0.0%	0.0%
Intangibles	$22.74M	$23.53M	$26.69M
YoY Change	-12.21%	-11.84%
Long-Term Investments
YoY Change
Other Assets	$926.0K	$886.0K	$1.006M
YoY Change	-12.23%	-11.93%	11.53%
Total Long-Term Assets	$54.04M	$54.87M	$61.35M
YoY Change	-8.27%	-10.56%	4.4%
TOTAL ASSETS
Total Short-Term Assets	$134.7M	$131.9M	$184.8M
Total Long-Term Assets	$54.04M	$54.87M	$61.35M
Total Assets	$188.7M	$186.7M	$246.1M
YoY Change	-17.95%	-24.13%	-13.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.076M	$2.556M	$2.429M
YoY Change	-40.21%	5.23%	-45.72%
Accrued Expenses	$9.952M	$12.19M	$9.682M
YoY Change	-25.86%	25.95%	28.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.07M	$15.59M	$12.11M
YoY Change	-18.83%	28.72%	-0.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.406M	$1.338M	$1.300M
YoY Change	10.02%	2.92%	-89.0%
Total Long-Term Liabilities	$1.406M	$1.338M	$1.300M
YoY Change	10.02%	2.92%	-89.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.07M	$15.59M	$12.11M
Total Long-Term Liabilities	$1.406M	$1.338M	$1.300M
Total Liabilities	$29.23M	$29.96M	$28.67M
YoY Change	-14.95%	4.51%	-6.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$217.1M	-$209.0M	-$145.2M
YoY Change	36.28%	43.94%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$159.3M	$156.6M	$217.2M
YoY Change
Total Liabilities & Shareholders Equity	$188.7M	$186.7M	$246.1M
YoY Change	-17.95%	-24.13%	-13.66%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$8.114M	-$16.93M	-$23.80M
YoY Change	-42.34%	-28.87%	-251.67%
Depreciation, Depletion And Amortization	$700.0K	$700.0K	$500.0K
YoY Change	0.0%	40.0%	-49.6%
Cash From Operating Activities	-$18.20M	-$12.01M	-$16.96M
YoY Change	62.61%	-29.2%	102.04%
INVESTING ACTIVITIES
Capital Expenditures	$114.0K	$192.0K	$3.023M
YoY Change	216.67%	-93.65%	-247.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$114.0K	-$192.0K	-$3.023M
YoY Change	216.67%	-93.65%	47.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	465.0K	358.0K	28.00K
YoY Change	910.87%	1178.57%
NET CHANGE
Cash From Operating Activities	-18.20M	-12.01M	-16.96M
Cash From Investing Activities	-114.0K	-192.0K	-3.023M
Cash From Financing Activities	465.0K	358.0K	28.00K
Net Change In Cash	-17.85M	-11.84M	-19.95M
YoY Change	59.62%	-40.66%	90.98%
FREE CASH FLOW
Cash From Operating Activities	-$18.20M	-$12.01M	-$16.96M
Capital Expenditures	$114.0K	$192.0K	$3.023M
Free Cash Flow	-$18.31M	-$12.20M	-$19.98M
YoY Change	63.11%	-38.95%	215.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	4523000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	156905000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	12209000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10962000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11821000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23527000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25108000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7286000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	886000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	882000	usd
CY2024Q2	us-gaap	Assets Assets	186749000	usd
CY2023Q4	us-gaap	Assets Assets	214506000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1601000	usd
CY2024Q2	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10278000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2024Q2	us-gaap	Deferred Income Current DeferredIncomeCurrent	839000	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1916000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15589000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12598000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1888000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	39184338	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	390273000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	386602000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-209010000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176590000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-24732000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-23315000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	156618000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	186784000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	172000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	211000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156790000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186749000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214506000	usd
CY2023Q4	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	4908000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9582000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	131879000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10654000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1823000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1338000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1325000	usd
CY2024Q2	brns	Deferred Tax Liability Net DeferredTaxLiabilityNet	490000	usd
CY2023Q4	brns	Deferred Tax Liability Net DeferredTaxLiabilityNet	574000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	29959000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27511000	usd
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39184338	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39184338	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38643540	shares
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	334000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11662000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13543000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7201000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13128000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	18863000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	26671000	usd
CY2024Q2	us-gaap	Other Operating Income OtherOperatingIncome	577000	usd
CY2023Q2	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18286000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26337000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	635000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	522000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	14000	usd
CY2024Q2	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	693000	usd
CY2023Q2	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	559000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	310000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1336000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1377000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16950000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24960000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1136000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-16931000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23802000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39041111	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38407672	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39041111	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38407672	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	164000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5604000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16779000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-18220000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-11000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-15000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16768000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18205000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1615000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	503000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1577000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-15520000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172016000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1195000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	358000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	164000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156790000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2222000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1789000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4580000	usd
CY2023Q1	brns	Shares Cancelled During Period Value Deferred Shares SharesCancelledDuringPeriodValueDeferredShares	0	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-18223000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	233569000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1990000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	123000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5604000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	217462000	usd
	us-gaap	Profit Loss ProfitLoss	-32463000	usd
	us-gaap	Profit Loss ProfitLoss	-42047000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2810000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4212000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2897000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2520000	usd
	brns	Non Cash Lease Expenses NonCashLeaseExpenses	717000	usd
	brns	Non Cash Lease Expenses NonCashLeaseExpenses	595000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	583000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7122000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	78000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	309000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	19000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	14000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-44000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1652000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5606000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-262000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3107000	usd
	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-352000	usd
	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-1586000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	967000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1916000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1140000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	275000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	839000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-819000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-138000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23828000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20131000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5530000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-500000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5530000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	861000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1880000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	163000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	861000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1717000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-849000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2589000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24316000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21355000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142090000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194385000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117774000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	173030000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	506000	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	0	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	282000	usd
	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	0	usd
	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	-47000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117800000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-209000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1100000	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4200000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7700000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
	us-gaap	Profit Loss ProfitLoss	-32463000	usd
	us-gaap	Profit Loss ProfitLoss	-42047000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-43000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-65000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-16931000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23802000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32420000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41982000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39041111	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38407672	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38907296	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38211625	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39041111	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38407672	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38907296	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38211625	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7779884	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6781099	shares
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	500000	usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	6400000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	1300000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	900000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000	usd
CY2024Q2	brns	Finite Lived Intangible Asset Expected Amortization Year Six FiniteLivedIntangibleAssetExpectedAmortizationYearSix	3200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3200000	usd
CY2024Q2	brns	Finite Lived Intangible Asset Expected Amortization Year Seven FiniteLivedIntangibleAssetExpectedAmortizationYearSeven	3200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3200000	usd
CY2024Q2	brns	Finite Lived Intangible Asset Expected Amortization Current Year FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear	3200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3200000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7813000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5402000	usd
CY2024Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1143000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	3031000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	626000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1474000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9582000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2024Q2	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	5124000	usd
CY2023Q4	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	4003000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1232000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2412000	usd
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	985000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	789000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1049000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	942000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1888000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1066000	usd
CY2024Q2	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10278000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
	us-gaap	Severance Costs1 SeveranceCosts1	800000	usd
CY2024Q1	us-gaap	Deferred Income DeferredIncome	1434000	usd
CY2023Q1	us-gaap	Deferred Income DeferredIncome	0	usd
CY2023Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q2	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
CY2023Q2	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	1629000	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
CY2024Q2	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	577000	usd
CY2023Q2	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	782000	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
CY2024Q2	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	18000	usd
CY2023Q2	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	8000	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
CY2024Q2	us-gaap	Deferred Income DeferredIncome	839000	usd
CY2023Q2	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q2	us-gaap	Deferred Income DeferredIncome	839000	usd
CY2023Q2	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q2	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q2	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q2	brns	Percentage Of Shares Necessary To Exercise Preemptive Rights PercentageOfSharesNecessaryToExercisePreemptiveRights	0.75
	brns	Period Of Preemptive Rights To Be Exercised PeriodOfPreemptiveRightsToBeExercised	P5Y
CY2023Q4	brns	Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre Emption Rights MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights	1928	gbp
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1951377	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2142905	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	229430	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	217860	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7779884	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.19
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5400000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6781099	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.51
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1195000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1990000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2810000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4212000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7286000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1916000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10654000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	819000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	442000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M15D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	151000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	303000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	358000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	316000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	717000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	595000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	358000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	467000	usd
	us-gaap	Lease Cost LeaseCost	717000	usd
	us-gaap	Lease Cost LeaseCost	898000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	958000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1928000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1952000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1977000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2003000	usd
CY2024Q2	brns	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	7979000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16797000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4227000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	12570000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001828185-24-000075-index-headers.html	Edgar Link	pending
0001828185-24-000075-index.html	Edgar Link	pending
0001828185-24-000075.txt	Edgar Link	pending
0001828185-24-000075-xbrl.zip	Edgar Link	pending
brns-20240630.htm	Edgar Link	pending
brns-20240630.xsd	Edgar Link	pending
brns-20240630xexx311.htm	Edgar Link	pending
brns-20240630xexx312.htm	Edgar Link	pending
brns-20240630xexx321.htm	Edgar Link	pending
brns-20240630_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
brns-20240630_cal.xml	Edgar Link	unprocessable
brns-20240630_def.xml	Edgar Link	unprocessable
brns-20240630_pre.xml	Edgar Link	unprocessable
brns-20240630_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brns-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRNS
Barinthus Biotherapeutics PLC Stock $brns

2024 Q3 Form 10-Q Financial Statement

#000182818524000075 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS Barinthus Biotherapeutics PLC Stock $brns

2024 Q3 Form 10-Q Financial Statement

#000182818524000075 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS
Barinthus Biotherapeutics PLC Stock $brns